
Gentian Diagnostics Investor Relations Material
Latest events

Q2 2025
Gentian Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gentian Diagnostics
Access all reports
Gentian Diagnostics ASA is a Norwegian company that specializes in the development and production of in-vitro diagnostic (IVD) reagents. The company’s focus is on creating biochemical reagents for use in clinical chemistry analyzers, particularly utilizing Particle-Enhanced Turbidimetric Immunoassays (PETIA). These assays enable faster, automated testing for various medical conditions, improving operational efficiency for clinical labs. Gentian’s products target key areas such as infections, inflammation, kidney disease, cardiac conditions, and veterinary medicine. Gentian Diagnostics is headquartered in Moss, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Gentian Diagnostics


Q4 2024
Gentian Diagnostics


Q2 2025
Gentian Diagnostics
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
GENT
Country
🇳🇴 Norway